Reference: https://www.nmn.com/news/nmn-protects-against-colon-cancer-new-study-finds
A recent study has highlighted the potential of nicotinamide mononucleotide (NMN) in preventing colon cancer. Researchers utilised a mouse model, inducing colon tumors through a combination of azoxymethane injections and dextran sulfate sodium to simulate inflammation-driven carcinogenesis.
Mice treated with NMN exhibited a significant reduction in tumor formation compared to their untreated counterparts, suggesting NMN's protective role against colon cancer development.
The study delved into the mechanisms behind NMN's protective effects, focusing on its impact on oxidative stress and inflammation—both key contributors to tumorigenesis. Untreated mice displayed elevated markers of DNA-damaging oxidative stress and inflammation within their colon tissues. In contrast, NMN-treated mice showed markedly lower levels of these harmful markers, indicating that NMN effectively mitigates gut inflammation and oxidative stress.
These findings suggest that NMN's antioxidative and anti-inflammatory properties play a crucial role in its ability to suppress tumor development in the colon.
While these preclinical results are promising, further research is necessary to determine the applicability of NMN as a preventive or therapeutic agent for colon cancer in humans.
Future studies should aim to explore the optimal dosing, safety, and efficacy of NMN in clinical settings, as well as its potential interactions with existing cancer treatments.
